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“Case Report: Potential Arsenic Toxicosis
Secondary to Herbal Kelp Supplement” by
Amster et al. (2007) is fundamentally
flawed, both scientifically and with regard to
the regulation of dietary supplements. 
Amster et al. (2007) claimed to have
found “detectable levels of arsenic in eight
of the nine kelp herbal supplements, rang-
ing from 1.59 ppm to 65.5 ppm by dry
weight (1.59, 2.28, 9.55, 9.97, 10.5, 24.1,
34.8, and 65.5 ppm),” with a median of
10.23 ppm. In this instance, concentrations
are irrelevant without disclosing the mass of
the capsules. This would allow for calcula-
tion of the potential exposure to arsenic; any
valid scientific argument on toxicity has to
be based on exposure levels and daily intake,
not on concentration.
For example, if we applied a 50-mg mass
as the capsule mass, this would equate to
arsenic concentrations of 0.0795, 0.114,
0.478, 0.499, 0.525, 1.21, 1.74, and
3.275 µg/capsule, respectively. With a serv-
ing of one capsule per day, this is well below
the normal daily intake cited by Amster
et al. (2007):
Nonoccupationally exposed individuals [had] an
average total (inorganic and methylated) arsenic
intake of 40 µg/day. U.S. dietary intake of inor-
ganic arsenic has been estimated to range from
1 to 20 µg/day (Schoof et al. 1999).
A 500-mg capsule, in effect multiplying the
daily intake 10-fold, would still result in all
the products below the average daily total
intake of 40 µg as cited by Amster et al.
(2007).
The glaring omission of the mass of the
capsules and the subsequent presentation of
the data as a concentration allowed Amster
et al. (2007) to provide a provocative story
and headline. Once the real-world metrics
are applied, however, the fog is dispersed
and these numbers are obviously well within
the numbers the authors cited as daily
intake values. These data are no longer
provocative and make it impossible for kelp
supplements to be painted as “unsafe” as the
authors suggested. 
Amster et al. (2007) also were not dili-
gent in researching kelp supplements, and
they overlooked key references. One
important oversight is the European
Pharmacopoeia (2006), which contains a
monograph on kelp supplements, with guide-
lines on arsenic concentration in kelp. The
European Pharmacopoeia sets a limit of
90 ppm total arsenic in kelp. Pharmacopoeial
monographs are developed over the course of
years by experts in the field. The sheer fact
that this reference was not cited by Amster
et al. (2007) further reveals their ignorance on
the subject.
The application of the Food and Drug
Administration (FDA) tolerance level for
arsenic as residue in muscle meat of chicken
and turkey, and in eggs (FDA 2006) in
terms of concentration used by Amster et al.
(2007) is also not applicable just on product
mass alone. For instance, a 4-oz serving of
turkey is converted to 113398.0924 mg.
Therefore, a 2-ppm limit is applicable and
logical based on the mass of the product.
This serving of 4 oz turkey at a 2-ppm
concentration would obviously result in
exponentially greater exposure to arsenic
(approximately 2,300 times greater) than a
50-mg kelp dietary supplement capsule at a
2-ppm concentration. To imply that there is
toxicity associated with anything—be it a
food, pharmaceutical, or dietary supple-
ment—without applying the appropriate
metrics is irresponsible and potentially dam-
aging, as well as confusing, to the consumer
who may benefit from that product.
In addition to the inappropriate use of
metrics, Amster et al. (2007) did not differ-
entiate between the different species of
arsenic present in the kelp samples. This
differentiation is significant since as the
authors themselves present, “In most cases
the toxic moiety is presumably trivalent
arsenic in the form of inorganic arsenious
acid (arsenite).” In fact, the California Clean
Drinking Water Act of 1986 (California
Environmental Protection Agency 1996),
commonly referred to as “Proposition 65,”
sets limits only on inorganic arsenic com-
pounds (oxides). This limit is set at
10 mg/day. The California Proposition 65
limit was determined by taking the no
observed effect level, which is defined as
“the highest level at which a chemical can be
administered to an organism without any
adverse effect (for example upon health,
growth, development, reproductive capacity
or lifetime) being observed” (California
Environmental Protection Agency 1996),
and then dividing by 1,000. In addition, the
Food Chemicals Codex (1996) has set a
limit of 3 ppm inorganic arsenic. There is
no limit for total or organic arsenic com-
pounds. The absence of blood arsenic at the
time of poisoning from the study (Amster
et al. 2007) is also a relevant and question-
able deficiency.
With respect to supplement regulation,
supplements must be accurately labeled as
mandated by the Dietary Supplement Health
and Education Act of 1994 (DSHEA 1994)
and actively monitored by the FDA.
Regulatory action is taken when and where
appropriate. The FDA, on a number of occa-
sions, has stated that the DSHEA provides all
the legislative authority needed to regulate
dietary supplements. In testimony before the
House of Representatives Committee on
Government Reform, Robert E. Brackett
(Center for Food Safety and Applied
Nutrition, FDA) stated that the 
FDA regulates the safety, manufacturing, and
labeling of dietary supplements, while [the
Federal Trade Commission] has primary responsi-
bility for regulating the advertising of these prod-
ucts.” (FDA 2005)
In conclusion, contrary to the viewpoint of
Amster et al. (2007), dietary supplements
are in fact regulated, have a well-established
history of safety, and are essential to the
health of the nation.
The author is employed by a trade association
representing the natural products industry.
Daniel Fabricant
Scientific and Regulatory Affairs
Natural Products Association
Washington, DC
E-mail: dfabricant@naturalproductsassoc.org
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Amster et al. (2007) reported findings from
a case study involving a possible link
between arsenic toxicity and the ingestion
of a kelp-based supplement. The authors
concluded that the arsenic-contaminated
supplement was the likely cause of the neu-
rologic, dermatologic, and gastrointestinal
symptoms in their patient. Although the
report has several methodologic shortcom-
ings, the most serious flaw is the authors’
failure to recognize that the arsenic most
commonly found in seaweed and seafood
products is relatively nontoxic. This is in
contrast to inorganic arsenic, which has
well-documented acute and chronic toxic-
ity. Amster et al. (2007) did not discuss the
possibility that the arsenic measured in the
kelp supplement was in the organic form,
nor did they address the great variability in
toxicity among arsenic compounds. These
two oversights lead to the unsupported con-
clusion that the arsenic found in kelp is
responsible for the unique set of medical
conditions observed in their patient.
Amster et al. (2007) stated that “all
chemical forms of arsenic eventually produce
the same toxic syndrome.” In fact, the toxi-
cologic properties of organic arsenic com-
pounds are very different from those of
inorganic arsenic. Inorganic arsenic is signifi-
cantly more toxic than pentavalent arsenic
compounds, arsenosugars, and arsenobetaine
[Agency for Toxic Substances and Disease
Registry (ATSDR) 2007b]. Arsenobetaine is
a common constituent of seafood and is con-
sidered nontoxic. Interestingly, the major
organic arsenic compounds in most seaweed
are arsenosugars, which are still much less
toxic than inorganic arsenic. For example, in
an in vitro cytotoxicity assay, inorganic
arsenic was 50 times more toxic than the
trivalent arsenosugar and > 600 times more
toxic than the pentavalent arsenosugar
(Andrewes et al. 2004). In a recent article on
speciated arsenic in seaweed, Rose et al.
(2007) confirmed that inorganic arsenic lev-
els in most varieties of seaweed are unde-
tectable. Thus, the assumption that organic
arsenic in the supplement could cause toxic-
ity consistent with inorganic arsenic is scien-
tifically unsupportable. 
Although Amster et al. (2007) did not
quantify an arsenic intake dose, they did
use urinary arsenic levels to estimate expo-
sure. They noted that normal levels of
arsenic in urine are 50 µg/g creatinine
(roughly equivalent to 50 µg As/L) and
that their patient had an elevated urinary
arsenic level of 85.5 µg/g creatinine.
According to the Agency for Toxic
Substance Registry (ATSDR 2000), nor-
mal urinary arsenic levels are 50 µg/L, but
only “in the absence of recent consumption
of seafood.” After seafood consumption,
arsenic urinary levels can reach 1,000 µg/L
(Vahter 1994). Thus, it is clear that
85.5 µg/g creatinine is not indicative of
arsenic toxicity, particularly after known
organic arsenic exposures. Many researchers
have investigated the relationship between
seafood consumption and urinary arsenic
and have concluded that in order to make
meaningful risk determinations through
arsenic urine analysis, individuals should
refrain from eating seafood (including sea-
weed) at least 4 days before testing (Foa
et al. 1984; Kales et al. 2006).
Moreover, the symptoms most promi-
nent in the patient described by Amster
et al. (2007)—memory loss, alopecia, and
fatigue—are not characteristic of arsenic
toxicity (ATSDR 2007b; National Research
Council 1999). The most sensitive non-
cancer end point of arsenic exposure is the
appearance of skin lesions (with very spe-
cific characteristics). Even these sensitive
manifestations of chronic inorganic arsenic
poisoning are not observed until lifetime
exposures are hundreds of micrograms of
arsenic per day (Abernathy et al. 2003).
There are several other limitations of the
study by Amster et al. (2007). For example,
the patient had manifestations of the condi-
tions even before supplement use. Also, the
authors did not discuss the possibility of
iodine toxicity associated with the supple-
ment ingestion. Certain comparisons the
authors drew between the arsenic in the sup-
plement and the regulatory limits are mis-
leading. In particular, the reference to the
Food and Drug Administration (FDA) food
standard for arsenic of 2 ppm, which applies
only to animals treated with veterinary
drugs, is not relevant (ATSDR 2007a). FDA
guidance recommends levels for seafood that
are much higher. For example, the level of
concern for total arsenic in crustaceans is
86 ppm, a concentration 10 times higher
than the amount found in the kelp supple-
ment (FDA 1993).
In conclusion, Amster et al. (2007) inap-
propriately relied on total arsenic data to link
arsenic exposure to disease. They used their
findings to comment on safety in the dietary
supplement industry as a whole, implying
that their results indicate that heavy metal
contamination in supplements is a major
health concern. Although contamination in
food and dietary supplements is an issue that
should be examined, their article did not
inform this issue, and it obscures more sig-
nificant food safety concerns that are of
greater public health significance.
The author is employed by Gradient
Corporation, an environmental consulting firm
that provides technical support to the regulated
community, regulators, and other parties with
scientific questions.
Ari S. Lewis
Gradient Corporation
Cambridge, Massachusetts
E-mail: alewis@gradientcorp.com
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Safe Use of Herbal Kelp
Supplements
doi:10.1289/ehp.10393
In their report of a 54-year-old woman with a
2-year history of worsening alopecia, memory
loss, and fatigue, Amster et al. (2007) attrib-
uted later-emerging symptoms to arsenic in a
kelp-containing (Laminaria digitata) supple-
ment. However, the authors failed to report
that the product was used at two to four
times the suggested amount, of potential sig-
nificance because of the naturally occurring
presence of iodine in kelp. Speciation of
arsenic into organic and inorganic forms was
not addressed, nor was the amount of arsenic
consumed calculated from observed concen-
tration levels. Also, there were errors in
marketplace and regulatory descriptions.
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Icelandic Kelp. The patient “initially took
two tablets,” which was later increased to “at
least four pills per day” (Amster et al. 2007).
The authors overlooked the product’s label,
which states that one tablet contains 225 µg
iodine (150% of daily value) and recom-
mends “one (1) tablet per day” (Nature's
Life, Larkspur, CA). This labeling conforms
to the federal regulation that limits daily
ingestion of kelp to an amount that provides
no more than 225 µg iodine [Food and Drug
Administration (FDA) 2006]. The product
label also includes the following statement: 
CAUTION: Do not exceed recommended
dosage without first consulting your healthcare
practitioner, as excess iodine may adversely affect
thyroid function.
In neglecting to mention the product’s
labeling and their patient’s decision to ignore
it, Amster et al. (2007) excluded important
information. Under federal law, supplement
marketers must disclose material facts associ-
ated with use of their products. When a con-
sumer ignores a label caution though, he or
she takes on responsibility for that decision.
Intake of iodine at least four times this
product’s recommended dose must be con-
sidered a potential factor in evaluating the
observed symptoms. Four tablets contain
900 µg iodine, 600% of its daily value.
Amster et al. (2007) noted that the patient
had a “more severe presentation than would
be expected” from the measured arsenic
level. In fact, of the several symptoms
recorded after the patient initiated use (and
overdose) of the product, only four symp-
toms—weakness, nausea, vomiting, and
possibly erythema—are identified in the
presented “clinical manifestations of chronic
arsenic exposure.” However, these same
symptoms, as well as headache and diarrhea—
also observed in this patient—are also asso-
ciated with iodine toxicity (Pease 1996),
albeit usually at higher doses. It would have
therefore been no more or less speculative to
declare that the patient had a "more severe
presentation than would be expected" from
the consumed iodine.
In their analysis Amster et al. (2007) did
not differentiate between organic and inor-
ganic arsenic. Arsenic is commonly found in
seaweeds used as food (Rose et al. 2007). With
the exception of hijiki, most arsenic found in
food seaweeds is the organic form, recognized
as less toxic than the inorganic form (Rose
et al. 2007). The European Pharmacopoeia
(European Pharmacopoeia Commission 2007)
allows up to 90 ppm arsenic in kelp used in
medicinal products, whereas food regulators
have advised that consumption of hijiki—but
not kelp or other seaweeds—be avoided due to
arsenic concentrations in this species (Food
Standards Agency 2004).
Although Amster et al. (2007) noted
that the arsenic concentration found in most
of the analyzed supplements exceeded FDA
tolerances for residues in meats and eggs,
they did not compare consumed arsenic
from these separate sources. Daily consump-
tion of 5 oz chicken—about one-half a
chicken breast [the amount of food from the
meat or beans group needed daily by
women > 51 years of age, according to the
U.S. Department of Agriculture’s (USDA)
current food pyramid (USDA 2007)]—at
the allowed arsenic concentration of
0.5 ppm would contain 71 µg arsenic. To
take in the same amount of arsenic from the
tested samples of Icelandic Kelp, the patient
would have needed to consume between 2 g
(at 34.8 ppm arsenic) and 45 g (at
1.59 ppm) of these tablets daily. Although
she may have used an amount at the lower
end of this range, her symptoms would be
just as likely to be observed in persons eating
more than half a chicken breast each day. 
Financial data that Amster et al. (2007)
attributed to Anonymous (2002) was mis-
stated; sales of supplements in 2001 reached
only about one-tenth of the reported
$178 billion. Additionally, the authors were
apparently uninformed about differences
between “homeopathic medications,” regu-
lated as drugs since 1938, and dietary sup-
plements, which have been placed in a
specific regulatory class only since 1994.
The authors’ reports of adulterated products
in Singapore (Tay and Seah 1975), England
(Mitchell-Heggs et al. 1990), and Brazil
(Mattos et al. 2006) are irrelevant to the
U.S. marketplace and its regulations, as is
the citation from a 1990 reference about
labeling of “botanical medicines” in light of
the 1994 law (Mitchell-Heggs et al. 1990),
which requires supplement labels to disclose
more information than conventional food
products. 
In conclusion, we have no disagreement
with the authors’ implication that marketers
have a responsibility to control the level of
potentially harmful contaminants in herbal
products. Inaccurate reporting and specula-
tive science, however, have no place in
safety evaluations of case reports associated
with supplements.
The authors are employees of a trade associa-
tion that represents the herbal products industry;
100% of their wages are provided by companies
in this trade. Some such companies sell products
that contain kelp. The manufacturer of Icelandic
Kelp is not a member of this trade association.
Michael McGuffin
Steven Dentali
American Herbal Products Association
Silver Spring, Maryland
E-mail: mmcguffin@ahpa.org
E-mail: sdentali@ahpa.org
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We are heartened by the feedback we have
received from concerned patients, health-care
professionals, herbal supplement retailers, and
government health officials regarding our
recent case study (Amster et al. 2007), but we
certainly understand the concern from the
representatives of the herbal trade industry.
We would like to take this opportunity to
respond to some of their comments. 
In their letter, McGuffin and Dentali
suggest that iodine was the cause of our
patient’s symptoms, a conclusion with which
we disagree. Daily intake of up to 500 µg
iodine does not clinically affect the thyroid.
Although it has been suggested that
1–2 mg/day is safe, there is also evidence that
much higher intakes are tolerated without
problems. In their comprehensive review of
this subject, Backer and Hollowell (2000)
concluded that “the strongest data suggest
that low levels of iodine (1–5 mg/day) are
safe for most people for years.” The 10th edi-
tion of the Recommended Dietary Allowances
(National Research Council 1989) suggested
a maximum allowable dietary intake of iodine
of 2 mg/day for adults, and Breecher and
Dworken (1986) noted that chronic toxicity
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Increased iodine intake (≤ 10 mg/day) may
cause hypothyroidism or hyperthyroidism,
but this condition is quite rare and is usually
associated with underlying risk factors such
as thyroiditis, subacute thyroiditis, or previ-
ously treated Graves disease. Intake of very
high concentrations (18 mg to > 1 g/day) has
been associated with iodine goiter (Wolff
1969).
Although we wonder how many cases of
hypothyroidism are caused by irresponsible
supplement use, in our case iodine toxicity is
not the most likely etiology. Our patient
(Amster et al. 2007) had normal thyroid
function tests on two different occasions
when hypothyroidism was being considered.
Furthermore, she fully recovered (especially
memory loss and fatigue) within 3 weeks
after discontinuation of the kelp supple-
ment. This short span of time for recovery
would most likely not occur if she had
iodine-induced hypothyroidism. In sum-
mary, the clinical presentation of this case
was not consistent with iodine toxicity, par-
ticularly at the dose ingested. It is our clini-
cal opinion, given the supporting clinical
history and laboratory evidence, that her
symptoms were more likely from the arsenic
found in her kelp supplement and not from
iodine. We believe this case raises legitimate
concerns about arsenic toxicosis from com-
mercially available kelp supplements and
that further testing is indicated. 
McGuffin and Dentali suggest that the
patient is to blame for taking more than the
recommended dose. We agree that the
patient has ultimate responsibility to stay
within the manufacturer’s guidelines, but
we wonder if our patient may have been
more careful in her self-prescribing if the
presence of potentially toxic levels of heavy
metals were included in the product label-
ing. This does, however, highlight a general
concern of herbal medications as they are
currently marketed and used: There is little
oversight from prescribing health practi-
tioners, and self-dosing commonly leads to
overdosing and possible adverse herb–drug
interactions (Bush et al. 2007). 
McGuffin and Dentali are correct that
our reporting of the dietary supplement
market share was indeed misstated. We
reported $178 billion from the Nutrition
Business Journal (Anonymous 2002), but
$17.8 billion is the correct figure. 
Our study (Amster et al. 2007) was not
intended to be a comprehensive survey of
arsenic content in commercial kelp supple-
ments, but rather to call attention to the large
variability of arsenic concentrations. In his
letter, Lewis suggests, without documenta-
tion, that “the arsenic most commonly found
in seaweed and seafood products is relatively
nontoxic,” that is, organic arsenic. In a recent
study on arsenic content in ethanolic kelp
and bladderwrack extracts, Krishna et al.
(Krishna MVB, Brewer TM, Marcus RK,
unpublished data) found that the majority
(90–95%) of the arsenic present was inor-
ganic arsenic, and only minor amounts of
arsenic (5–10% of the total arsenic) were
dimethyl arsenic acid. This finding suggests
that the majority of arsenic in kelp supple-
ments is the more toxic inorganic arsenic. 
McGuffin and Dentali, representatives
from the American Herbal Products
Association, point out the difference between
homeopathic and herbal therapies. We agree
that there are differences, but for the purpose
of our study there are obvious similarities:
Both are used for medicinal purposes on a
nonprescription basis and have been found to
have toxic levels of heavy metals. McGuffin
and Dentali are correct to point out that
homeopathic medicines are regulated in a
similar fashion to allopathic medicinals, as
opposed to dietary supplements, which under
the Dietary Supplement Health and
Education Act of 1994 (DSHEA 1994) lack
regulatory standards for premarket approval,
good manufacturing standards, and labeling
of indication (Borneman and Field 2006).
In conclusion, it was in no way our
intention to attack the complementary alter-
native medicine community. Fortunately we
all agree that the supplement industry has a
responsibility to control the level of poten-
tially harmful contaminants in their prod-
ucts. However, if the majority of certain
herbal supplements have detectable levels of
toxic metals—as is the case in our and other
studies on kelp—then perhaps we should
not leave the responsibility to the industry
itself, but instead encourage our govern-
ment to regulate these medicinals the same
as all other medications, and not as dietary
supplements. 
The authors declare they have no competing
financial interests.
Marc Schenker
Eric Amster
UC Davis School of Medicine
University of California
Davis, California
E-mail: mbschenker@ucdavis.edu
Asheesh Tiwary
UC Davis School of Veterinary Medicine
University of California
Davis, California
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In the November Focus article
[“Carbon Capture and Storage:
Blue-Sky Technology or Just
Blowing Smoke? Environ Health
Perspect 115:A538–A545 (2007)],
Jeff Chapman, chief executive officer
of the Carbon Capture and Storage
Association, suggested €62 billion as
the potential annual, not cumula-
tive, revenue from the European car-
bon dioxide cap-and-trade system.